Advances of chimeric antigen receptor T-cell immunotherapy combined with immune checkpoint inhibitors in malignancies therapy
10.3969/j.issn.1000-8179.2018.09.113
- VernacularTitle:嵌合抗原受体T细胞联合免疫检查点抑制剂治疗恶性肿瘤的研究进展
- Author:
Yaqing CAO
1
;
Xin JIN
;
Songnan SUI
Author Information
1. 天津医科大学一中心临床医学院
- Keywords:
chimeric antigen receptor T-cell;
immune checkpoint inhibitors;
combination therapy;
malignancy
- From:
Chinese Journal of Clinical Oncology
2018;45(9):472-476
- CountryChina
- Language:Chinese
-
Abstract:
Recent years,chimeric antigen receptor T-cell(CAR-T)therapy has made great strides in enabling better treatment of malig-nant tumors,especially hematological tumors,as well as increasing the research prospects of potential solid tumor therapies.Conse-quently,CAR-T therapy is expected to become the selected treatment for patients with relapsed and refractory tumors.Immune check-point inhibitors also have certain curative effects in the treatment of cancers,such as liver cancer,refractory Hodgkin's lymphoma,and other malignant tumors,which brings promise to patients with advanced cancer.However,both treatments have different degrees of limitations.Recent clinical trials suggest that combined immune checkpoint inhibitors impair the immunosuppressive effects of the tu-mor microenvironment,increase the efficacy of CAR-T therapy,and prolong the survival.This article will review the research progress on the combination of CAR-T immunotherapy and immune checkpoint inhibitors in malignancies theray.
